Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United Kingdom

Abstract

The purpose of this analysis was to assess potential predictors of intra-cranial bleeding (ICB) and gastrointestinal bleeding (GIB) in patients with symptomatic peripheral artery disease (PAD) in UK primary care. Patients with symptomatic PAD diagnosed from 2000 to 2010 were identified from The Health Improvement Network (THIN; N = 28,484). A nested case–control analysis, adjusted for potential confounders, was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for potential predictors of ICB or GIB. For GIB, follow-up was restricted to Hospital Episode Statistics-linked THIN practices. Median follow-up was 6 years. For ICB (153 cases), the OR (95% CI) was 3.85 (1.33–11.13) for previous ICB, 0.90 (0.61–1.34) for treated hypertension, 1.59 (0.65–3.87) for untreated hypertension and 1.38 (0.80–2.36) for current smoking. ORs for ICB were 0.78 (0.50–1.21), 0.40 (0.09–1.82) and 1.27 (0.47–3.47) with use of acetylsalicylic acid (ASA), clopidogrel and warfarin monotherapy, respectively, compared with non-use of such therapy. For GIB (506 cases), the OR was 1.40 (1.05–1.86) for peptic ulcer disease, 3.20 (1.81–5.64) for dual anti-platelet therapy use, 1.96 (1.46–2.64) for non-steroidal anti-inflammatory drug (NSAID) use and 1.01 (0.80–1.28) for proton pump inhibitor use. ORs for GIB were 1.78 (1.39–2.30), 2.03 (1.05–3.93) and 1.25 (0.72–2.16) with ASA, clopidogrel and warfarin monotherapy, respectively, compared with non-use. Previous ICB was a risk factor for ICB. Use of anti-platelet therapy or NSAIDs increased GIB risk. Identifying bleeding predictors could help optimize treatment strategies for patients with PAD.

Keywords

gastrointestinal bleeding - intra-cranial bleeding - observational study - primary care database - symptomatic peripheral artery disease

• References

• 1 Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124 (01) 17-23
• 2 Patel MR, Becker RC, Wojdyla DM. , et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol 2015; 22 (06) 734-742
• 3 Sigvant B, Hasvold P, Kragsterman B. , et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: results from a Swedish nationwide study. J Vasc Surg 2017; 66 (02) 507-514
• 4 Cea Soriano L, Fowkes FGR, Johansson S, Allum AM, García Rodriguez LA. Cardiovascular outcomes for patients with symptomatic peripheral artery disease: a cohort study in The Health Improvement Network (THIN) in the UK. Eur J Prev Cardiol 2017; 24 (18) 1927-1937
• 5 Gerhard-Herman MD, Gornik HL, Barrett C. , et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135 (12) e726-e779
• 6 Tendera M, Aboyans V, Bartelink ML. , et al; European Stroke Organisation; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32 (22) 2851-2906
• 7 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
• 8 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
• 9 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 10 Hu PT, Lopes RD, Stevens SR. , et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trial. J Am Heart Assoc 2017; 6 (01) e004699
• 11 Jones WS, Hellkamp AS, Halperin J. , et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014; 35 (04) 242-249
• 12 IMS Health Inc. Our data: THIN. Available at: http://wwwepic-ukorg/our-data/our-datashtml . Accessed June 15, 2017
• 13 Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996; 75-79
• 14 In Practice Systems Ltd. Gemscript. Available at: http://wwwinpscouk/ . Accessed June 15, 2017
• 15 UK National Health Service (NHS). Hospital Episode Statistics (HES). Available at: http://content.digital.nhs.uk/hes . Accessed June 15, 2017
• 16 Cea-Soriano L, Fowkes FGR, Johansson S, Allum AM, García Rodriguez LA. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open 2018; 8 (01) e018184
• 17 National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management (CG147); 2012 . Available at: https://www.nice.org.uk/guidance/cg147/resources/peripheral-arterial-disease-diagnosis-and-management-35109575873989 . Accessed November 3, 2017
• 18 Gaist D, Wallander MA, González-Pérez A, García-Rodríguez LA. Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2013; 22 (02) 176-182
• 19 Pearce N. What does the odds ratio estimate in a case-control study?. Int J Epidemiol 1993; 22 (06) 1189-1192
• 20 Townsend P, Phillimore M, Beattie A. Health and Deprivation: Inequality and the North. London: Croom Helm Ltd; 1988
• 21 Baumann F, Husmann M, Benenati JF, Katzen BT, Del Conde I. Bleeding risk profile in patients with symptomatic peripheral artery disease. J Endovasc Ther 2016; 23 (03) 468-471
• 22 Dodson JA, Petrone A, Gagnon DR, Tinetti ME, Krumholz HM, Gaziano JM. Incidence and determinants of traumatic intracranial bleeding among older veterans receiving warfarin for atrial fibrillation. JAMA Cardiol 2016; 1 (01) 65-72
• 23 Barochiner J, Aparicio LS, Waisman GD. Challenges associated with peripheral arterial disease in women. Vasc Health Risk Manag 2014; 10: 115-128
• 24 Bhatt DL, Scheiman J, Abraham NS. , et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52 (18) 1502-1517
• 25 Anand SS, Bosch J, Eikelboom JW. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; DOI: 10.1016/S0140-6736(17)32409-1.
• 26 Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12 (03) 171-177
• 27 Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16 (04) 393-401